Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

What Does a "Lilly Pulitzer Girl" Look Like? The Spring 2026 Runway Has a Refreshed Answer

The 65-year-old brand is ready to evolve.

Marie Claire

Eli Lilly Stock Joins the $1 Trillion Club as LLY Hits New All-Time Highs

Eli Lilly (LLY) just became the first healthcare company to join the $1 trillion market cap club. Shares are trading at a new all-time high on Friday, Nov. 21. The stock is up 40% in the past year and nearly 80% in the past two years. Analysts remain highly confident,...

Barchart

Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers

Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong technical momentum and is trading at new all-time highs. Shares are up 43% over the past year. Analyst sentiment is overwhelmingly positive, with most major firms rating LLY...

Barchart

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring

Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry.

Benzinga

Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight

Hedge funds appear to be rebuilding their defensive playbook, and perhaps the clearest tell is a subtle but broad rotation into heavyweight healthcare names. Recent 13F filings show renewed interest in large-cap pharma and managed-care stocks—a shift that could set up a fresh wave of inflows into healthcare ETFs after…

Benzinga

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs

Eli Lilly And Co (NYSE:LLY) has officially become the giant quietly moving the strings behind a large slice of the pharma ETF universe. With blockbuster revenue growth, repeated earnings beats and a pipeline that refuses to slow down, Lilly isn’t just lifting its own stock – it’s powering a growing…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since

Eli Lilly's blockbuster drug Zepbound could be getting a big new customer: Medicare. See the implications of the company's recent deal with President Trump.

MarketBeat

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Eli Lilly Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees.

Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

Dave Ricks, CEO of pharmaceutical giant Eli Lilly and Co. (NYSE:LLY), delivered a scathing critique of pharmacy benefit managers (PBMs), accusing the industry’s “middle actors” of “rent taking” and creating a “terrible incentive” structure that caused insulin list prices to skyrocket.

Benzinga

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration

MeiraGTx Holdings plc (NASDAQ:MGTX) stock is trading higher after the company inked a strategic collaboration in the area of ophthalmology with Eli Lilly and Co. (NYSE:LLY).

Benzinga

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

Benzinga

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Eli Lilly Posts Stellar Q3: Long-Term Upside Is Well in Play

Eli Lilly just posted its fastest revenue growth ever, putting shares up 40% in less than three months. The stock continues to have strong long-term potential.

Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Benzinga

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Barchart

'Our GPUs Are Everywhere’ According to CEO Jensen Huang as Nvidia Doubles Down on AI, Quantum, and 6G

Nvidia stock continues to surge higher as the AI chipmaker widens its moat significantly.

The Independent UK

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

Benzinga

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

International Business Times

LLY Stock Update: Eli Lilly Shares Hold Firm Amid Strong Earnings

Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year.

Benzinga

Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis

Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis.

Benzinga

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.